Advanced Search


Study ID Status Title Patient Level Data
101468/243 Completed A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome (RLS) Study Listed on
101468/248 Completed An Open-Label Extension Study with REQUIP (ropinirole) CR for Subjects from Studies 101468/165, 101468/168 and 101468/169 Study Listed on
101468/249 Completed A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Study Listed on
101468/253 Completed A study to determine the tolerability and pharmacokinetics for ropinirole in paediatric / adolescent patients with RLS (Type 2) Study Listed on
101468/902 Completed A study to evaluate the effect of repeated oral doses of ropinirole on cardiac conduction as assessed by 12-lead electrocardiogram compared to placebo and single oral doses of moxifloxacin (Bayer) as a positive control. Study Listed on
101469 Completed An Open-Label, Prospective Study to Assess the Efficacy, Safety and Tolerability of 36 weeks Lamotrigine in the Prevention of Mood Episodes in Subjects with Bipolar Disorder, who are in remission following a manic/hypomanic index episode or a depressive index episode.
101477 Completed Assess the immunogenicity and reactogenicity of a booster dose of a formulation of GSK Biologicals’ DTPw-HBV/Hib vaccine at 15-18 mths of age in infants previously primed with the same vaccine
101497 Completed A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg - 300mg once daily), Extended-Release Venlafaxine Hydrochloride (75mg - 150mg once daily) and Placebo in Subjects with Major Depressive Disorder. Study Listed on
101501 Completed An exploratory, open, randomized, phase I-II study to evaluate the safety and the immune responses to VZV induced by an investigational vaccination regimen or a live attenuated OKA VZV vaccine in adult subjects aged 18-30 years and in adult subjects aged 50-70 years
101518 Completed A phase IV, open, multicentre study to assess the immunogenicity and reactogenicity of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix-hexa) given as a booster at 18-24 months of age to children who have received a three-dose primary immunisation course with the same vaccine in a previous study
101555 Completed A phase II, double-blind, randomized, placebo-controlled study to compare the immunogenicity, reactogenicity and safety of 2 different formulations of GSK Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV Study Listed on
101563 Completed Tomodensitometric evaluation using multi-detector computerised tomography (MDCT) of bronchial and parenchymatous structures in asthmatic subjects before and after treatment with salmeterol/fluticasone propionate 50/250 Diskus one inhalation twice daily. Open-label, 3-month study
101653 Completed A centre-randomized, open-label, cross-over study to compare the pharmaco-economic consequences of an Ultiva (remifentanil hydrochloride) based regimen with conventional sedative based regimens in ICU subjects requiring short-term mechanical ventilation with analgesia and sedation
101695 Ext. Mth30 Completed Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs Study Listed on
101722 Completed Prospective, national, multicentre, non comparative study evaluating the improvement of urinary symptoms, discomfort and quality of life in subjects with benign prostatic hyperplasia (BPH) after 24 weeks of treatment by dutasteride.
101724 Completed A randomized, double blind, double dummy, parallel group, placebo controlled study to evaluate the pharmacodynamic and pharmacokinetic response and safety and tolerability of SB424323 (250mg, 375mg and 500 mg) administered twice daily for 16 weeks, on top of asprin (325mg, qd) in men and women with non valvular atrial fibrillation at a low or intermediate risk for stroke
101731 Completed Interest of early combination with rosiglitazone in the optimized management of type 2 diabetic subjects poorly controlled with sulfonylurea or metformin monotherapy. OPTIMA study.
101732 Completed AVANTAGE: Monitoring a patient cohort treated with Avandia – Evaluation of safety data.
101735 Completed A pharmacokinetic study to evaluate the intra-ocular penetration of aciclovir following single, oral dose of valaciclovir in subjects undergoing cataract surgery
101765 Completed Comparison of the action of the rosiglitazone-metformin fixed-dose combination and of a metformin-sulfonylurea free combination on the b-cell function in type 2 diabetic patients not controlled with metformin alone.
101822 Completed A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)
101824 Completed A single-centre, randomized, double blind, placebo-controlled, double-dummy, dose escalating cross-over study to examine the safety, tolerability, systemic pharmacokinetic profile and pharmacodynamics of single inhaled doses of a new chemical entity and salmeterol (50 µg via DPI) in COPD patients. Study Listed on
101853 Completed A randomized, controlled, phase II study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ investigational vaccination regimen, when administered intramuscularly as a 3-dose primary immunization (2-3-4 month schedule) before 6 months of age. Study Listed on
101858 Completed Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix® and Prevnar®, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune® at 3 to 5 years Study Listed on
101877 Completed A randomised, open label, 5-way crossover study to assess the systemic exposure of FP and salmeterol from SERETIDE/ADVAIR 250 without spacer, with Aerochamber -Plus and with -Max spacer, with VOLUMATIC spacer and SERETIDE/ADVAIR 500 DISKUS/ACCUHALER in adult subjects with mild or intermittent asthma Study Listed on



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.